Tivozanib

Tivozanib is an oral cancer drug sold under the brand name Fotivda that belongs to the tyrosine kinase inhibitor family. Chemically a quinoline urea derivative, it suppresses angiogenesis, the growth of new blood vessels that tumors need to expand, by inhibiting all three vascular endothelial growth factor receptors rather than just one. It was approved in the European Union in August 2017 and later by the United States Food and Drug Administration in March 2021, both times for advanced renal cell carcinoma, the most common form of kidney cancer, specifically for patients whose disease had progressed after at least two earlier systemic therapies. Tivozanib is taken as a capsule by mouth. In clinical trials, common side effects included high blood pressure in roughly half of patients, voice changes, fatigue and diarrhea each in about a quarter of patients, along with reduced appetite, nausea, low thyroid hormone, cough and mouth inflammation.